TMPRSS2 and COVID-19: While a reduction in the efficacy of proxalutamide could be expected due to the P.1 variant's typical resistance to usual care for COVID-19, since all the three major aspects of the P.1 variant (high dependence on TMPRSS2 for cell entry, dysfunctional exacerbated inflammatory and immunologic reactions, and severe endothelial dysfunction) seem to be specially targeted by an anti-androgen [41,42], the high efficacy of proxalutamide in the P.1 variant could also be justified by these peculiarities of the variant present in the RCTs.